Table 1 GO and KEGG pathway enrichment analysis for identified DEGs
From: Identification of novel gene and pathway targets for human epilepsy treatment
Category | Term | Count | p value |
|---|---|---|---|
Up-regulated genes | |||
GOTERM_BP_FAT | GO:0050877 ~ neurological system process | 26 | 2.15E−04 |
GOTERM_BP_FAT | GO:0019226 ~ transmission of nerve impulse | 22 | 2.01E−11 |
GOTERM_BP_FAT | GO:0006811 ~ ion transport | 21 | 4.75E−05 |
GOTERM_BP_FAT | GO:0007267 ~ cell–cell signaling | 20 | 4.97E−06 |
GOTERM_BP_FAT | GO:0007268 ~ synaptic transmission | 19 | 5.63E−10 |
GOTERM_CC_FAT | GO:0031224 ~ intrinsic to membrane | 70 | 0.007687949 |
GOTERM_CC_FAT | GO:0016021 ~ integral to membrane | 65 | 0.030340215 |
GOTERM_CC_FAT | GO:0005886 ~ plasma membrane | 63 | 4.81E−06 |
GOTERM_CC_FAT | GO:0044459 ~ plasma membrane part | 48 | 9.49E−08 |
GOTERM_CC_FAT | GO:0005887 ~ integral to plasma membrane | 23 | 0.00337979 |
GOTERM_MF_FAT | GO:0005216 ~ ion channel activity | 15 | 1.16E−05 |
GOTERM_MF_FAT | GO:0022838 ~ substrate specific channel activity | 15 | 1.63E−05 |
GOTERM_MF_FAT | GO:0015267 ~ channel activity | 15 | 2.40E−05 |
GOTERM_MF_FAT | GO:0022803 ~ passive transmembrane transporter activity | 15 | 2.46E−05 |
GOTERM_MF_FAT | GO:0022836 ~ gated channel activity | 13 | 2.69E−05 |
KEGG_PATHWAY | hsa04720:Long-term potentiation | 7 | 1.89E−05 |
KEGG_PATHWAY | hsa05014:Amyotrophic lateral sclerosis (ALS) | 5 | 9.61E−04 |
KEGG_PATHWAY | hsa04020:Calcium signaling pathway | 7 | 0.003316868 |
KEGG_PATHWAY | hsa04080:Neuroactive ligand-receptor interaction | 8 | 0.005123351 |
KEGG_PATHWAY | hsa04310:Wnt signaling pathway | 5 | 0.037620947 |
Down-regulated genes | |||
GOTERM_BP_FAT | GO:0006955 ~ immune response | 40 | 1.23E−16 |
GOTERM_BP_FAT | GO:0006952 ~ defense response | 30 | 1.65E−10 |
GOTERM_BP_FAT | GO:0009611 ~ response to wounding | 26 | 3.53E−09 |
GOTERM_BP_FAT | GO:0007155 ~ cell adhesion | 26 | 7.74E−07 |
GOTERM_BP_FAT | GO:0022610 ~ biological adhesion | 26 | 7.94E−07 |
GOTERM_MF_FAT | GO:0005198 ~ structural molecule activity | 20 | 4.49E−05 |
GOTERM_MF_FAT | GO:0005509 ~ calcium ion binding | 18 | 0.018905046 |
GOTERM_MF_FAT | GO:0005201 ~ extracellular matrix structural constituent | 13 | 1.09E−10 |
GOTERM_MF_FAT | GO:0042802 ~ identical protein binding | 13 | 0.041784269 |
GOTERM_MF_FAT | GO:0004857 ~ enzyme inhibitor activity | 12 | 1.53E−04 |
GOTERM_CC_FAT | GO:0005576 ~ extracellular region | 70 | 4.18E−15 |
GOTERM_CC_FAT | GO:0005886 ~ plasma membrane | 69 | 0.002166744 |
GOTERM_CC_FAT | GO:0044421 ~ extracellular region part | 50 | 4.52E−17 |
GOTERM_CC_FAT | GO:0005615 ~ extracellular space | 30 | 2.56E−08 |
GOTERM_CC_FAT | GO:0005578 ~ proteinaceous extracellular matrix | 28 | 1.34E−14 |
KEGG_PATHWAY | hsa04510:Focal adhesion | 16 | 4.33E−07 |
KEGG_PATHWAY | hsa05322:Systemic lupus erythematosus | 14 | 3.27E−09 |
KEGG_PATHWAY | hsa04610:Complement and coagulation cascades | 13 | 4.92E−10 |
KEGG_PATHWAY | hsa04512:ECM-receptor interaction | 13 | 5.21E−09 |
KEGG_PATHWAY | hsa04060:Cytokine–cytokine receptor interaction | 10 | 0.02253563 |